NF-kappa beta upregulates ADAMTS5 expression by direct binding after TNF-alpha treatment in OUMS-27 chondrosarcoma cell line

Abstract

Inflammation caused-aggrecan degradation is a critical event in the pathogenesis of osteoarthritis (OA). The aggrecanases like a disintegrin and metalloproteinase with thrombospondin motifs 5 (ADAMTS5) are assumed to be key players in the aggrecan destruction. To develop the comprehensive therapy method for OA, it is essential to elucidate the activation mechanism of ADAMTS5 gene after stimulation of inflammatory cytokines like tumor necrosis factor-alpha (TNF-alpha). The cell lines of human chondrosarcoma (OUMS-27) and embryonic kidney (HEK293T) were incubated with tumor necrosis factor-alpha (TNF-alpha) for certain time periods, and the expression level of ADAMTS5 was measured in both mRNA and protein levels. Tissue-specific ADAMTS5 activation was founded to be induced after TNF-alpha treatment. Then, the constructs for the promoter region of ADAMTS5 were prepared and luciferase assay was conducted to understand the involvement mechanism of nuclear factor-kappa beta (NF-& x138;beta) in ADAMTS5 activation. It was demonstrated that NF-& x138;beta induces the ADAMTS5 expression level by directly binding the promoter region of ADAMTS5. Although the TNF-alpha blocker is used for OA treatment, the development of a more comprehensive treatment strategy is an urgent need. Our experimental data contributes in terms of selecting NF-& x138;beta as a target molecule. Up to date, NF-& x138;beta has been proven to involve in the ADAMTS5 up-regulation after several pro-inflammatory cytokines stimulation. In conclusion, our findings make important contributions to the knowledge about the roles of NF-& x138;beta in ADAMTS5 activation under inflammatory conditions. So, NF-& x138;beta could be considered to be a potential target for OA treatment.